ClinicalTrials.gg
RecruitingNCT06891365Updated Apr 7, 2026

Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases

A Phase 1 interventional study of NNC0581-0001 and Placebo (NNC0581-0001) in Healthy Volunteers and Hepatic Steatosis, sponsored by Novo Nordisk A/S. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 44 studies in Fatty Liver with a site in United Kingdom — 16 open to participants now, 19 under way, 4 of them phase 3. Fatty Liver · United Kingdom.

Planned enrollment
20th of 34
48 · median 81
Started
2025
with 5 others
Phase 1
5 of 44
2 open now
Primary completion
2027-10
later than 9 of 18 live
Registered
40th of 44
by date
Lead sponsor
2 of 44
Novo Nordisk A/S

Among the 44 studies in Fatty Liver with a site in United Kingdom, this one is the 20th largest by planned enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2025, is one of 5 in phase 1, reaches primary completion later than 9 of the 18 other live ones, and was the 40th registered.

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 186 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

16 of the 44 studies in Fatty Liver with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Fatty Liver with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of NNC0581-0001 in participants with hepatic steatosis and suspected steatohepatitis (increased liver fat and suspected inflammation). NNC0581-0001 will be given in 2 different dose levels as injection under the skin (once per month for 3 months). Participants will either get NNC0581-001 or Placebo (dummy treatment). Which treatment participants get is decided by chance. NNC0581-0001 is a new medicine which cannot be prescribed by doctors. The study will last about 58 weeks.

03

Conditions studied

  • Healthy Volunteers
  • Hepatic Steatosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Considered eligible based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.
  • Male or female (of non-) aged 18-69 years (both inclusive) at the time of signing the .
  • (BMI) greater than or equal to (>=) 25.0 at screening.
  • Liver fat content measured by magnetic resonance imaging - estimated proton density fat fraction (MRI-PDFF) >= 10 percent at screening.

Additional inclusion criteria for participants in the open-label liver cohort apply:

  • (ALT) in men greater than (>) 30 units per liter (U/L), women > 19 U/L
  • Liverstiffness, measured by FibroScan® (VCTE) > 8 kPa and less than (\<) 12 kPa
  • Informed consent obtained at screening for a liver biopsy to be performed at baseline and post-treatment.

Note: Participants with confirmed metabolic dysfunction-associated steatohepatitis (MASH), based on a prior liver biopsy, can be included in the open-label cohort.

Exclusion criteria

Exclusion Criteria:

  • Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
  • Any laboratory safety parameter, at screening, outside the extended laboratory ranges, and considered per the principal investigator (see laboratory provided reference ranges for specific values). Of note, re-screening or re-sampling is NOT allowed if the individual has failed one of the exclusion criteria related to the following laboratory parameters:
  • >= 3 × (ULN)
  • Aspartate aminotransferase (AST) >= 3 × ULN
  • > 1.5 × ULN
  • Estimated (eGFR) \< 50 milliliter per minute per 1.73 square meters (mL/min/1.73 m\^2) at screening.

Additional exclusion criteria for participants in the open-label liver group apply:

  • Medical history of abnormal bleeding
  • > 34.9 kilograms per square meters (kg/m\^2)
  • Presence of ascites
  • Cirrhosis based on screening tests or historical biopsy
  • Lab abnormalities of count \< 150 × 10\^9 per liter or (INR) > 1.2
  • Concomitant use of medication:
  • anticoagulants or herbal supplements with an anticoagulative effect (as judged by the principal investigator)
  • antiplatelet medications
  • exception for aspirin that must be stopped 5 days prior to procedure and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that must not be taken within 3 days of the procedure.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Cohort 1: NNC0581-0001 (Dose 1)

    Participants will receive a subcutaneous (s.c) injection of either NNC0581-0001 Dose 1 or a matching placebo once monthly.

    Drug: NNC0581-0001 · Drug: Placebo (NNC0581-0001)

  • Experimental
    Cohort 2: NNC0581-0001 (Dose 2)

    Participants will receive a s.c injection of either NNC0581-0001 Dose 2 or a matching placebo once monthly.

    Drug: NNC0581-0001 · Drug: Placebo (NNC0581-0001)

Interventions

  • DrugNNC0581-0001

    NNC0581-0001 will be administered subcutaneously.

  • DrugPlacebo (NNC0581-0001)

    Placebo matched to NNC0581-0001 will be administered subcutaneously.

06

What researchers measure

Primary outcomes

  1. Number of treatment emergent adverse events (TEAEs)

    Measured as count of events.

    Time frame: From 1st dose (day 1) until completion of the end of study visit at week 52

Secondary outcomes

  1. AUC0-32h: The area under the NNC0581-0001 plasma concentration-time curve from time zero to 32 hours after each of the three doses

    Measured in nanogram hour per mililitre (ng\*h/mL).

    Time frame: From dosing (day 1 in each treatment period) to 32 hours post dose

  2. Cmax: The maximum concentration of NNC0581-0001 in plasma after each dose of three doses

    Measured in nanogram per mililitre(ng/mL).

    Time frame: From dosing (day 1 in each treatment period) to 32 hours post dose

  3. Tmax: The time from dose administration to maximum plasma concentration of NNC0581-0001 after each dose of three doses

    Measured in hours.

    Time frame: From dosing (day 1 in each treatment period) to 32 hours post dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Oct 2027, 30 months after the start.

Of 22 phase 1 interventional studies under Fatty Liver, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 30 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Mar 24, 2025
StartActual
Mar 12, 2025
Primary completionEst.
Oct 11, 2027
CompletionEst.
Nov 15, 2027
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06891365
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
Mar 12, 2025
Primary completion
Oct 11, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Apr 7, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion